Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
100 participants
OBSERVATIONAL
2024-08-20
2026-10-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Urinary Biomarkers of Renal Injury in Inflammatory Bowel Disease
NCT04282577
The Percent of AKI Occurred in Patient with Comorbidities Undergoing Colonoscopy
NCT06743815
Systemic Activation of Inflammasomes and Frailty in Older Candidates to Kidney Transplantation
NCT06887075
Parameters of the Recovery Time of Acute Kidney Injury in Critically Ill Patients
NCT06114693
Neutrophil-to-Lymphocyte and Platelet-to-lymphocyte Ratios as a Predictor Factors for Chronic Kidney Disease Progression
NCT06670599
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
IBD is profoundly associated with extra intestinal manifestions , Especially renal and urinary involvement occurs in 4% - 23% of patients with IBD.
Patterns of renal complications include nephrolithiasis, glomerulonephritis, amyloidosis, AKl, CKD, tubulointerstitial nephritis, asymptomatic proteinuria and hematuria; each type has specific mechanism
Nephrolithiasis is 10-100 times greater in IBD patients than general population.most common stones are calcium, oxalate and urate; Stones occur due to loss of electrolytes "Mg,k" due to diarrhea which lead to crystallization.
Glomerulonephritis pattern in IBD , is associated with IgA nephropathy, IgM nephropathy, membranous and focal segmental glomerulonephritis.
There is genetic connection between IgA nephropathy and intestinal diseases!
Secondary amyloidosis (AA-type) is a rare but serious complication of IBD.renal amyloidosis had been proven to be the most common lethal manifestion of IBD - associated amyloidosis (A), since renal involvement rapidly leads to end stage renal failure.
Sever long -standing IBD consists a predisposing factor for renal complications that occur in 4-23 % of patients So we aim to shed more light on the pathophysiology of renal damage in IBD; considering the renal manifestions and complications of IBD, it is important to emphasize the role of screening of renal function in preventing, diagnosing, and,if possible, reversing probable kidney damage.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
CROSS_SECTIONAL
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rania Essam Mohamed
Assistant Lecturer
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Mohamed Hassan, Staff doctor
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Renal and urinary in IBD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.